Targeting HIF-1α and hypoxia-related effector molecules could impair cancer cell survival by attenuating glucose metabolic processes or inhibiting VEGF-induced angiogenesis and survival-promoting signaling pathways. This evidence concerns the gene VEGFA and cancer.